On 18 October, we announced an investment by Eight Roads in Eywa Pharma, a Singapore-based generic pharmaceutical company. Envestor Ventures and our associated fund, F-Prime, also took part in the $30m round.
Eywa was set up in 2015 to provide reliable and affordable generic pharmaceuticals for patients globally. It has established subsidiaries in India, the US and the UK and is currently building a portfolio of products for the US and Europe. It has also established a state-of-the-art R&D centre in Chennai for the development of finished dosage forms.
Prem Pavoor will join Eywa's board and said: "We remain excited about the generics pharmaceutical opportunity in the US and Europe. We believe that a team that brings a strong combination of product portfolio selection, supply chain and regulatory expertise will find success in these geographies, despite competition. Eight Roads Ventures looks forward to partnering with the founders Srinivasan and Jayakumar in this phase of Eywa's growth."